Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,181.90
(
-0.24%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 28
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: masterlongevity post# 120708

Sunday, 05/29/2011 12:06:17 PM

Sunday, May 29, 2011 12:06:17 PM

Post# of 257300
One more concern I see about bapi phase II data is the lack of dose response related to efficacy* (in contrast to safety where vasogenic edema was dose-related).

*Both efficacy and vasogenic edema were related to ApoE4.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today